DeepMed Research

Glucagon

Generic Name: Glucagon

Brand Names: Baqsimi, Glucagen, Gvoke, Ogluo

Drug Type: Biotech

CAS Number: 16941-32-5

Unique Ingredient Identifier: 76LA80IG2G

Background: Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.

Glucagon was granted FDA approval on 14 November 1960.

Indication: Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.

Associated Conditions: Severe Hypoglycemia

Clinical Trials

A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes

Phase 1

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: Glucagon Nasal Powder [Baqsimi]

First Posted Date: 2021-08-05

Last Posted Date: 2024-05-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 7

Registration Number: NCT04992312

Locations: 🇺🇸
St. Luke's Regional Medical Center, Boise, Idaho, United States
🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 5 locations

Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 Diabetes

Phase 4

Completed

Conditions: Type 1 Diabetes

Interventions: Drug: Glucagon
Device: Closed-loop System

First Posted Date: 2021-07-02

Last Posted Date: 2022-08-18

Lead Sponsor: Steno Diabetes Center Copenhagen

Target Recruit Count: 11

Registration Number: NCT04949867

Locations: 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark
🇩🇰
Herlev Hospital, Herlev, Denmark

The Effect of Lifestyle-induced Hepatic Steatosis on Glucagon-stimulated Amino Acid Turnover

Not Applicable

Completed

Conditions: Glucagon Resistance
Non-Alcoholic Fatty Liver Disease

Interventions: Drug: Glucagon

First Posted Date: 2021-04-26

Last Posted Date: 2023-05-11

Lead Sponsor: Malte Palm Suppli, MD

Target Recruit Count: 20

Registration Number: NCT04859322

Locations: 🇩🇰
Center for Clinical Metabolic Research, Hellerup, Copenhagen, Denmark

A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes

Early Phase 1

Completed

Conditions: Type 1 Diabetes Mellitus With Hypoglycemia

Interventions: Drug: Insulin
Drug: Glucagon

First Posted Date: 2021-01-15

Last Posted Date: 2021-01-15

Lead Sponsor: Abvance Therapeutics

Target Recruit Count: 15

Registration Number: NCT04712266

Locations: 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States

Glucagon Regulation of Glucose Metabolism

Phase 1

Completed

Conditions: Insulin Secretion

Interventions: Drug: Glucagon

First Posted Date: 2020-04-15

Last Posted Date: 2021-05-14

Lead Sponsor: David D'Alessio, M.D.

Target Recruit Count: 19

Registration Number: NCT04347252

Locations: 🇺🇸
Duke Center for Living, Durham, North Carolina, United States

Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants With Type 2 Diabetes

Phase 4

Conditions: Type 2 Diabetes
Obesity

First Posted Date: 2020-03-13

Last Posted Date: 2022-02-01

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Target Recruit Count: 16

Registration Number: NCT04307797

Locations: 🇬🇧
Cambridge University Hospitals NHS Foundation Trust and The University of Cambridge, Cambridge, Cambridgeshire, United Kingdom

Effect of Physiologic Hyperglucogonemia on Adipocyte Metabolism

Early Phase 1

Completed

Conditions: Insulin Sensitivity

Interventions: Drug: Glucagon Infusion
Other: Saline

First Posted Date: 2020-03-09

Last Posted Date: 2024-10-21

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Target Recruit Count: 10

Registration Number: NCT04300049

Locations: 🇺🇸
South Texas Veterans Health Care Center, San Antonio, Texas, United States
🇺🇸
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

Dual-hormone Closed-loop Glucose Control in Type 1 Diabetes

Phase 4

Completed

Conditions: Type 1 Diabetes
Hypoglycemia

Interventions: Device: Closed-loop system
Drug: Glucagon

First Posted Date: 2019-08-12

Last Posted Date: 2022-08-18

Lead Sponsor: Steno Diabetes Center Copenhagen

Target Recruit Count: 13

Registration Number: NCT04053712

Locations: 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark

Mini-Dose Glucagon to Treat Fasting-induced Hypoglycemia During Ramadan

Not Applicable

Completed

Conditions: Fasting Hypoglycemia
Diabetes Mellitus, Type 1

Interventions: Drug: Glucagon Injection
Other: Glucose Tablets

First Posted Date: 2019-06-03

Last Posted Date: 2021-07-15

Lead Sponsor: Qassim University

Target Recruit Count: 20

Registration Number: NCT03970772

Locations: 🇸🇦
Qassim University, Buraydah, Saudi Arabia

The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Biological: Glucagon
Other: Control Study

First Posted Date: 2019-05-28

Last Posted Date: 2024-11-26

Lead Sponsor: Yale University

Target Recruit Count: 10

Registration Number: NCT03965130

Locations: 🇺🇸
Yale Hospital reserach Unit / YCCI, New Haven, Connecticut, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy